BEARINGPOINT
12.9.2019 09:22:09 CEST | Business Wire | Press release
Almost ten years to the day after the management buyout (MBO) that established the independent, Partner-led management and technology consultancy in 2009, BearingPoint announced that it has launched its Strategy 2025 for even greater success in the decade ahead. Three major ambitions drive the Strategy 2025: to put people in the center, to outperform the market every year and enable European clients to become global leaders, and to be within the top three players in key areas of expertise. Cornerstones of the strategy are to focus on five key areas in consulting for a clear differentiation in the market, to generate new revenue streams with intellectual property, to build critical mass within all practices, to accelerate the growth of BearingPoint’s solutions business, to foster greater collaboration between communities for more innovation, to leverage new business models and ecosystems, and to recruit, develop and retain the best talent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005072/en/
“It’s our firm’s 10th anniversary since we executed our management buyout back in 2009 and created the independent BearingPoint partnership, which I am proud to be part of today. Our Strategy 2025 builds on our existing strengths and puts people first. It outlines clear ambitions for the years ahead and focuses our business and differentiates us in the market,” said Kiumars Hamidian, Managing Partner of BearingPoint. “We are a European success story because of our strong client relationships, our intellectual property, and our people culture, and I am confident that our Strategy 2025 will keep the success going for us and our clients.”
BearingPoint had record revenues of €738 million in 2018 and has grown to more than 4,500 people. The firm said its Strategy 2025 is closely aligned to the market so that growth remains steady and profitable.
Strategy: Focus & Differentiate
BearingPoint said it is building on and further expanding the strengths that differentiate it: the firm’s culture and principles, its management and technology capabilities, its ability to create IP within ecosystems, and its independence and European roots.
“IP creation is something that we already have in our DNA,” said Kiumars, “and we will emphasize this much more. We want to make sure that the great work done on projects is leveraged across the firm from everyone at BearingPoint. Our people-centric approach is characterized by collaboration and communication and reflected in three dimensions: our clients, where we want to focus on the people aspect behind business transformation; our people, where we want to ensure that BearingPoint is the best place to develop and grow; and the communities around us, where we want to make a positive impact.”
BearingPoint structured its operating model into three units. The first unit covers the consulting business with a clear focus on key areas to drive growth across all regions. Earlier this year, BearingPoint established Business Services as a second unit in which it provides IP-driven managed services beyond SaaS and offers business critical services to support the business success of clients. The third business unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
To create synergies, BearingPoint also combined its practices into three regions: FBLA (France, Belgium, Luxembourg, Africa) led by Eric Falque, GSA (Germany, Switzerland, Austria) led by Iris Grewe, and GROW (Ireland, United Kingdom, Italy, Sweden, Finland, Norway, Netherlands) led by James Rodger. The firm said it seeks to have critical mass in all its practices, which means having at least 100 people in each practice.
The new operating model took effect on September 1.
Management Changes
Matthias Loebich will lead the Markets area of the Consulting unit that comprises all its industry segments. Damien Palacci is leading the Consulting Portfolio, which helps functions of companies with innovative offerings. Patrick Palmgren will lead the newly created business unit covering solutions, M&A activities, and ventures.
Donald Wachs, who leads the Business Services unit, and Damien Palacci have joined the Management Committee of BearingPoint.
About BearingPoint
BearingPoint
is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 75 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
Annual Report: www.bearingpoint.com/en/about-us/annual-report/
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005072/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
